Ponatinib in Advanced NSCLC w/ RET Translocations

Inclusion Criteria: * Histologically or cytologically confirmed advanced NSCLC * Molecular confirmation of a RET translocation * At least one measurable lesion as defined by RECIST * No restriction on number of prior therapies * Estimated life expectancy of at least 12 weeks * Able to swallow and retain orally administered medication * Must agree to use an effective form of contraception from enrollment through 30 days after the end of study treatment * Willingness and ability to comply with scheduled visits and study procedures Exclusion Criteria: * Clinically significant gastrointestinal abnormalities * Pregnant or breastfeeding * Major surgery within 28 days of initiating therapy * History of CNS disease (Note: Participants with brain metastases will be eligible if treated appropriately and if they remain clinically stable). * Anti-cancer therapy within 3 weeks * History of significant bleeding disorder unrelated to cancer * History of acute pancreatitis within 1 year of study entry or history of chronic pancreatitis * History of alcohol abuse * Uncontrolled hypertriglyceridemia * History of arterial thrombotic events (myocardial infarction, stroke or peripheral vascular disease). * Uncontrolled hypertension * Taking medications that are known to be associated with Torsades de Pointes * Ongoing active infection * Diagnosed with or received anti-cancer therapy for another primary malignancy within 3 years prior to entry (except for non-melanoma skin cancer or in situ cancers) * Any condition or illness tha could compromise patient safety or interfere with the evaluation of the drug